AMARIN CORP PLC -ADR
AMRNNASDAQTrading Snapshot
- Day Range
- $10.53 β $11.18
- 52-Week Range
- $11.15 β $17.31
- Volume (shares)
- 177,908
- Avg Volume (shares)
- β
- Shares Outstanding
- 422.5M
- Next Earnings
- 2027-02-23
Fundamentals Snapshot
- Annual Revenue
- $214M
- Last Q Revenue
- $40M
- P/E Ratio
- β
- P/S Ratio
- 1.3x
- EPS (TTM)
- $-0.05
- Dividend Yield
- β
- Dilution (1yr)
- +1.2%
AMARIN CORP PLC -ADR
AMRNAbout AMARIN CORP PLC -ADR
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

Amarin: 3 Key Takeaways for Long-Term Investors
Amarin reported its first profitable quarter in two years during Q3. European in-market demand for VAZKEPA grew 68% year over year.

Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted new clinical data

Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark
AMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.

Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript

What Amarin (AMRN) Said on Its Q3 Earnings Call
Amarin NASDAQ: AMRN reported its first profitable quarter in two years for the third quarter of 2026, as lower operating expenses, positive operating cash flow and growth in international in-market demand helped offset c

Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
DUBLIN and BRIDGEWATER, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results f